These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 11031409)

  • 1. Systemic adoptive T-cell immunotherapy in recurrent and metastatic carcinoma of the head and neck: a phase 1 study.
    To WC; Wood BG; Krauss JC; Strome M; Esclamado RM; Lavertu P; Dasko D; Kim JA; Plautz GE; Leff BE; Smith V; Sandstrom-Wakeling K; Shu S
    Arch Otolaryngol Head Neck Surg; 2000 Oct; 126(10):1225-31. PubMed ID: 11031409
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systemic T cell adoptive immunotherapy of malignant gliomas.
    Plautz GE; Barnett GH; Miller DW; Cohen BH; Prayson RA; Krauss JC; Luciano M; Kangisser DB; Shu S
    J Neurosurg; 1998 Jul; 89(1):42-51. PubMed ID: 9647171
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adoptive immunotherapy in patients with recurrent malignant glioma: preliminary results of using autologous whole-tumor vaccine plus granulocyte-macrophage colony-stimulating factor and adoptive transfer of anti-CD3-activated lymphocytes.
    Sloan AE; Dansey R; Zamorano L; Barger G; Hamm C; Diaz F; Baynes R; Wood G
    Neurosurg Focus; 2000 Dec; 9(6):e9. PubMed ID: 16817692
    [TBL] [Abstract][Full Text] [Related]  

  • 4. T-cell adoptive immunotherapy of metastatic renal cell carcinoma.
    Plautz GE; Bukowski RM; Novick AC; Klein EA; Kursh ED; Olencki TE; Yetman RJ; Pienkny A; Sandstrom K; Shu S
    Urology; 1999 Oct; 54(4):617-23; discussion 623-4. PubMed ID: 10510917
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adoptive immunotherapy with vaccine-primed lymph node cells secondarily activated with anti-CD3 and interleukin-2.
    Chang AE; Aruga A; Cameron MJ; Sondak VK; Normolle DP; Fox BA; Shu S
    J Clin Oncol; 1997 Feb; 15(2):796-807. PubMed ID: 9053507
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Generation of therapeutic T cells from draining lymph nodes in a murine model of head and neck squamous cell carcinoma.
    Sadeghi N; Black MJ; Hier MP; Shenouda G; Karp SE
    Arch Otolaryngol Head Neck Surg; 1997 Jan; 123(1):25-30. PubMed ID: 9006500
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I trial of combined immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor, low-dose interleukin 2, and interferon alpha in progressive metastatic melanoma and renal cell carcinoma.
    de Gast GC; Klümpen HJ; Vyth-Dreese FA; Kersten MJ; Verra NC; Sein J; Batchelor D; Nooijen WJ; Schornagel JH
    Clin Cancer Res; 2000 Apr; 6(4):1267-72. PubMed ID: 10778950
    [TBL] [Abstract][Full Text] [Related]  

  • 8. T cell adoptive immunotherapy of newly diagnosed gliomas.
    Plautz GE; Miller DW; Barnett GH; Stevens GH; Maffett S; Kim J; Cohen PA; Shu S
    Clin Cancer Res; 2000 Jun; 6(6):2209-18. PubMed ID: 10873070
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bimodal ex vivo expansion of T cells from patients with head and neck squamous cell carcinoma: a prerequisite for adoptive cell transfer.
    Junker N; Andersen MH; Wenandy L; Dombernowsky SL; Kiss K; Sørensen CH; Therkildsen MH; Von Buchwald C; Andersen E; Straten PT; Svane IM
    Cytotherapy; 2011 Aug; 13(7):822-34. PubMed ID: 21428850
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cellular immunotherapy for patients with metastatic colorectal carcinoma using lymph node lymphocytes localized in vivo by radiolabeled monoclonal antibody.
    Kim JA; Bresler HS; Martin EW; Aldrich W; Heffelfinger M; Triozzi PL
    Cancer; 1999 Jul; 86(1):22-30. PubMed ID: 10391559
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical observations on adoptive immunotherapy with vaccine-primed T-lymphocytes secondarily sensitized to tumor in vitro.
    Chang AE; Yoshizawa H; Sakai K; Cameron MJ; Sondak VK; Shu S
    Cancer Res; 1993 Mar; 53(5):1043-50. PubMed ID: 8439951
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Generation of vaccine-primed lymphocytes for the treatment of head and neck cancer.
    Chang AE; Li Q; Jiang G; Teknos TN; Chepeha DB; Bradford CR
    Head Neck; 2003 Mar; 25(3):198-209. PubMed ID: 12599287
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I dose escalation trial of MAGE-A3- and HPV16-specific peptide immunomodulatory vaccines in patients with recurrent/metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN).
    Zandberg DP; Rollins S; Goloubeva O; Morales RE; Tan M; Taylor R; Wolf JS; Schumaker LM; Cullen KJ; Zimrin A; Ord R; Lubek JE; Suntharalingam M; Papadimitriou JC; Mann D; Strome SE; Edelman MJ
    Cancer Immunol Immunother; 2015 Mar; 64(3):367-79. PubMed ID: 25537079
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjuvant therapeutic vaccination in patients with non-small cell lung cancer made lymphopenic and reconstituted with autologous PBMC: first clinical experience and evidence of an immune response.
    Rüttinger D; van den Engel NK; Winter H; Schlemmer M; Pohla H; Grützner S; Wagner B; Schendel DJ; Fox BA; Jauch KW; Hatz RA
    J Transl Med; 2007 Sep; 5():43. PubMed ID: 17868452
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adoptive cellular immunotherapy for non-small cell lung cancer: a pilot study.
    Chan B; Lee W; Hu CX; Ng P; Li KW; Lo G; Ho G; Yeung DW; Woo D
    Cytotherapy; 2003; 5(1):46-54. PubMed ID: 12745587
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Maintenance immunotherapy in recurrent or metastatic squamous cell carcinoma of the head and neck.
    Recchia F; Candeloro G; Di Staso M; Necozione S; Bisegna R; Bratta M; Tombolini V; Rea S
    J Immunother; 2008 May; 31(4):413-9. PubMed ID: 18391754
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II trial of autologous tumor vaccination, anti-CD3-activated vaccine-primed lymphocytes, and interleukin-2 in stage IV renal cell cancer.
    Chang AE; Li Q; Jiang G; Sayre DM; Braun TM; Redman BG
    J Clin Oncol; 2003 Mar; 21(5):884-90. PubMed ID: 12610189
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I trial of concurrent hyperfractionated split course radiotherapy (HFx RT), cisplatin (cDDP), and paclitaxel in patients with recurrent, previously irradiated, or treatment-naïve locally advanced upper aerodigestive malignancy.
    Langer CJ; Duffy K; Horwitz EM; Litwin S; Rosvold E; Schol J; Keenan E; Nicolaou N; Friedman CD; Ridge JA
    Cancer Invest; 2006 Mar; 24(2):164-73. PubMed ID: 16537186
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-dose chemotherapy and adoptive immunotherapy in the treatment of recurrent pediatric brain tumors.
    Peres E; Wood GW; Poulik J; Baynes R; Sood S; Abidi MH; Klein J; Bhambhani K; Dansey R; Abella E
    Neuropediatrics; 2008 Jun; 39(3):151-6. PubMed ID: 18991194
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunotherapy with effector cells and IL-2 of lymph node metastases of human squamous-cell carcinoma of the head and neck established in nude mice.
    Chikamatsu K; Reichert TE; Kashii Y; Saito T; Kawashiri S; Yamamoto E; Whiteside TL
    Int J Cancer; 1999 Aug; 82(4):532-7. PubMed ID: 10404067
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.